The AHA today urged the Centers for Medicare & Medicaid Services to suspend the pain-related questions in the Value-Based Purchasing Program while the agency works to address concerns the questions may inadvertently contribute to the opioid epidemic. The three questions are part of the Hospital Consumer Assessment of Healthcare Providers and Services. “The AHA agrees that the HCAHPS survey should inquire about pain management, that performance scores should be publicly reported, and that redesigned pain questions should eventually be reincorporated into the VBP program,” wrote Ashley Thompson, AHA senior vice president of public policy analysis and development. “However, we also want to ensure that the questions do not create pressure to prescribe opioids or other prescription painkillers or punish providers who, in their best judgment, choose not to prescribe them.”

Related News Articles

Perspective
Public
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
The Food and Drug Administration has identified a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus…
Headline
Thomas McGinn, M.D., senior executive vice president and chief physician executive officer at CommonSpirit Health, shares how the organization aligns…
Headline
The Food and Drug Administration Feb. 3 released an early alert on a heart pump issue from certain Abiomed products. The agency said Abiomed found its Impella…
Headline
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase…
Headline
The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for…